Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever

Nat Med. 2017 Oct;23(10):1146-1149. doi: 10.1038/nm.4396. Epub 2017 Sep 4.


There are no approved treatments for Lassa fever, which is endemic to the same regions of West Africa that were recently devastated by Ebola. Here we show that a combination of human monoclonal antibodies that cross-react with the glycoproteins of all four clades of Lassa virus is able to rescue 100% of cynomolgus macaques when treatment is initiated at advanced stages of disease, including up to 8 d after challenge.

MeSH terms

  • Animals
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Neutralizing / therapeutic use*
  • Antibodies, Viral / therapeutic use*
  • Cross Reactions
  • Enzyme-Linked Immunosorbent Assay
  • Humans
  • Immune Evasion / genetics
  • Immunohistochemistry
  • Lassa Fever / prevention & control*
  • Lassa virus / genetics
  • Macaca fascicularis
  • RNA, Viral / blood
  • Random Allocation
  • Survival Rate
  • Viral Load


  • Antibodies, Monoclonal
  • Antibodies, Neutralizing
  • Antibodies, Viral
  • RNA, Viral